{"id":"dapagliflozin-pill","safety":{"commonSideEffects":[{"rate":"10-15","effect":"Genital mycotic infections"},{"rate":"5-10","effect":"Urinary tract infections"},{"rate":"5-8","effect":"Polyuria"},{"rate":"0.1-0.2","effect":"Diabetic ketoacidosis"},{"rate":"2-5","effect":"Volume depletion"}]},"_chembl":{"chemblId":"CHEMBL429910","moleculeType":"Small molecule","molecularWeight":"408.88"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"SGLT2 is responsible for reabsorbing filtered glucose in the proximal tubule of the kidney. By blocking this transporter, dapagliflozin prevents glucose reabsorption, allowing excess glucose to be excreted in the urine. This mechanism reduces blood glucose independently of insulin secretion and also promotes modest weight loss and blood pressure reduction through osmotic diuresis.","oneSentence":"Dapagliflozin inhibits sodium-glucose cotransporter 2 (SGLT2) in the kidney to increase urinary glucose excretion and lower blood glucose levels.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:08:32.675Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"},{"name":"Heart failure with reduced ejection fraction"},{"name":"Chronic kidney disease"}]},"trialDetails":[{"nctId":"NCT07323524","phase":"PHASE4","title":"Dapagliflozin in Active Lupus Nephritis","status":"NOT_YET_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2026-02-01","conditions":"Lupus Nephritis (LN)","enrollment":33},{"nctId":"NCT04735042","phase":"","title":"SGLT-2 and DPP-4 Inhibition, Subclinical Inflammation of the Genito-urinary Tract and Risk of Infections.","status":"COMPLETED","sponsor":"University of Pisa","startDate":"2020-10-07","conditions":"Type 2 Diabetes, Urinary Tract Infections","enrollment":60},{"nctId":"NCT06719661","phase":"NA","title":"The Impact of Clinical Pharmacist Intervention and Dapagliflozin as Add-On Therapy in the Management of Type 2 Diabetes Mellitus.","status":"COMPLETED","sponsor":"University of Sulaimani","startDate":"2024-12-01","conditions":"Type 2 Diabetes Mellitus (T2DM)","enrollment":138},{"nctId":"NCT03899402","phase":"PHASE2, PHASE3","title":"Triple Therapy in T1DM","status":"ACTIVE_NOT_RECRUITING","sponsor":"State University of New York at Buffalo","startDate":"2019-05-01","conditions":"Type 1 Diabetes Mellitus","enrollment":78},{"nctId":"NCT06000462","phase":"PHASE4","title":"The Effect of Dapagliflozin on Weight Loss in Obese Adults Without Diabetes","status":"ACTIVE_NOT_RECRUITING","sponsor":"Oman Ministry of Health","startDate":"2024-04-22","conditions":"Obesity, Dapagliflozin Adverse Reaction, Weight Loss","enrollment":150},{"nctId":"NCT04792190","phase":"PHASE4","title":"Use of Dapagliflozin to Reduce Burden of Atrial Fibrillation in Patients Undergoing Catheter Ablation of Symptomatic Atrial Fibrillation","status":"COMPLETED","sponsor":"University of Rochester","startDate":"2021-07-27","conditions":"Atrial Fibrillation","enrollment":25},{"nctId":"NCT06373523","phase":"EARLY_PHASE1","title":"MASLD in Primary Hypothyroidism and Efficacy of Dapaglifozin","status":"NOT_YET_RECRUITING","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2024-09-01","conditions":"Hepatic Steato-Fibrosis, Non-Alcoholic Fatty Liver Disease","enrollment":60},{"nctId":"NCT04333823","phase":"PHASE3","title":"Adolescent Type 1 Diabetes Treatment With SGLT2i for hyperglycEMia & hyPerfilTration Trial","status":"UNKNOWN","sponsor":"The Hospital for Sick Children","startDate":"2020-12-11","conditions":"Diabetes Mellitus, Type 1","enrollment":100},{"nctId":"NCT05998525","phase":"PHASE3","title":"Dapagliflozin Effects on Coronary Calcium and Epicardial Fat Assessed by Cardiotomography","status":"COMPLETED","sponsor":"Hilda Elizabeth Macías Cervantes","startDate":"2021-06-21","conditions":"Diabete Type 2, Unstable Angina, Myocardial Infarction","enrollment":54},{"nctId":"NCT05194592","phase":"PHASE4","title":"Comparison of the Effects of Dapagliflozin and Gemigliptin on Ketone Metabolism and Cardiac Remodeling in Type 2 Diabetes","status":"UNKNOWN","sponsor":"Wonju Severance Christian Hospital","startDate":"2022-01-07","conditions":"Type2 Diabetes, Remodeling, Ventricular","enrollment":122},{"nctId":"NCT02211742","phase":"PHASE4","title":"Dapagliflozin in Type 1 Diabetes","status":"COMPLETED","sponsor":"Medical University Innsbruck","startDate":"2014-08","conditions":"Fasting Glucose, Glucose Excursion, Glycemic Control","enrollment":12},{"nctId":"NCT02796170","phase":"PHASE4","title":"Inhibition of Urinary Angiotensinogen and the Reduction of Blood Pressure by SGLT2 Inhibition in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Tulane University School of Medicine","startDate":"2016-03","conditions":"Type 2 Diabetes, Hypertension","enrollment":11},{"nctId":"NCT05440591","phase":"PHASE4","title":"Effects of Dapagliflozin and Metformin on Vascular Function in Newly-Diagnosed Treatment-Naive Type 2 Diabetes","status":"UNKNOWN","sponsor":"Tan Tock Seng Hospital","startDate":"2019-04-01","conditions":"Diabetes","enrollment":150},{"nctId":"NCT02235298","phase":"PHASE4","title":"Dapagliflozin Effects on Epicardial Fat","status":"COMPLETED","sponsor":"University of Miami","startDate":"2015-09","conditions":"Type 2 Diabetes","enrollment":100},{"nctId":"NCT02635386","phase":"PHASE3","title":"EQW, DAPA, EQW/DAPA, DAPA/MET ER and PHEN/TPM ER in Obese Women With PolycysticOvary Syndrome (PCOS)","status":"COMPLETED","sponsor":"Woman's","startDate":"2016-03-22","conditions":"Polycystic Ovary Syndrome, Obesity","enrollment":119},{"nctId":"NCT04195243","phase":"PHASE3","title":"Dapagliflozin vs Empagliflozin on Flow Mediated Dilation in Type 2 Diabetes Mellitus","status":"UNKNOWN","sponsor":"Centro Universitario de Ciencias de la Salud, Mexico","startDate":"2019-12-02","conditions":"Type 2 Diabetes Mellitus","enrollment":24}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Forxiga","Dapagliflozin"],"phase":"phase_3","status":"active","brandName":"Dapagliflozin Pill","genericName":"Dapagliflozin Pill","companyName":"Centro Universitario de Ciencias de la Salud, Mexico","companyId":"centro-universitario-de-ciencias-de-la-salud-mexico","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Dapagliflozin is a small molecule that inhibits the sodium/glucose cotransporter 2, a mechanism that is used to treat conditions such as type 2 diabetes. It is available in a 10mg tablet form and has been studied for its effects on weight loss in obese adults without diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}